Text Size

Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Asthmatic Patients

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00127166
First received: June 30, 2005
Last updated: April 7, 2010
Last verified: April 2010
History of Changes
Results First Received: June 16, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Exercise Induced Asthma
Interventions: Drug: montelukast sodium
Drug: Comparator: salmeterol
Drug: Comparator: fluticasone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Multicenter Study (30 Ex-US sites) Study Initiation Date: December 22, 2005 Study Completion Date: November 14, 2008

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

For randomization, patients fulfilled the following criteria:

  1. Forced Expiratory Volume in one second (FEV1) ≥70% predicted while withholding beta (β)-agonist for at least 6 hours
  2. Exercise-induced bronchoconstriction (EIB) showing FEV1 ≥15% reduction from baseline while on inhaled corticosteroids demonstrated twice during the run-in period.

Reporting Groups
  Description
Montelukast / Salmeterol

Period I- Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks.

Period II- Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks.

Inhaled Fluticasone 100 mcg twice daily throughout the study.
Salmeterol / Montelukast

Period I- Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks.

Period II- Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks.

Inhaled Fluticasone 100 mcg twice daily throughout the study.

Participant Flow for 3 periods

 Period 1:   Period I
    Montelukast / Salmeterol     Salmeterol / Montelukast  
STARTED     78     76  
COMPLETED     75     74  
NOT COMPLETED     3     2  
Protocol Violation                 0                 2  
Withdrawal by Subject                 2                 0  
Patient did not meet inclusion criteria                 1                 0  

Period 2:   Washout Period
    Montelukast / Salmeterol     Salmeterol / Montelukast  
STARTED     75     74  
COMPLETED     75     73  
NOT COMPLETED     0     1  
Patient did not meet inclusion criteria                 0                 1  

Period 3:   Period II
    Montelukast / Salmeterol     Salmeterol / Montelukast  
STARTED     75     73  
COMPLETED     72     73  
NOT COMPLETED     3     0  
Withdrawal by Subject                 2                 0  
Patient did not perform Visit 6 exercise                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Montelukast / Salmeterol

Period I- Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks.

Period II- Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks.

Inhaled Fluticasone 100 mcg twice daily throughout the study.
Salmeterol / Montelukast

Period I- Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks.

Period II- Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks.

Inhaled Fluticasone 100 mcg twice daily throughout the study.
Total Total of all reporting groups

Baseline Measures
    Montelukast / Salmeterol     Salmeterol / Montelukast     Total  
Number of Participants  
[units: participants]
 		  78     76     154  
Age  
[units: years]
Mean ± Standard Deviation 		  10.2  ± 2.0     9.8  ± 2.0     10.0  ± 2.0  
Gender  
[units: participants]
 		     
Female     35     30     65  
Male     43     46     89  
Race/Ethnicity, Customized  
[units: participants]
 		     
Asian     1     0     1  
Black     11     7     18  
White     38     41     79  
Other     28     28     56  
Area Under the Curve from 0 to 20 minutes (AUC0-20) [1]
[units: Percent times Minutes]
Mean ± Standard Deviation 		  320.08  ± 208.62     317.74  ± 165.71     318.93  ± 188.06  
Avg %-Change from Pre-Exercise Baseline FEV1 After 1st β-agonist use & Prior to 2nd β-agonist use  
[units: Percent change from baseline]
Mean ± Standard Deviation 		  1.36  ± 10.99     4.78  ± 10.92     3.05  ± 11.05  
Maximum Forced Expiratory Volume in one second (FEV1) Percent Predicted  
[units: Percent of predicted value]
Mean ± Standard Deviation 		  99.88  ± 32.45     100.54  ± 15.61     100.21  ± 25.49  
Maximum Percent Fall in Forced Expiratory Volume in one second (FEV1) After Exercise  
[units: Percent change from baseline]
Mean ± Standard Deviation 		  24.77  ± 10.25     25.42  ± 9.04     25.09  ± 9.65  
Time to Recovery  
[units: Minutes]
Mean ± Standard Deviation 		  23.53  ± 10.53     21.51  ± 8.30     22.53  ± 9.51  
[1] Area Under the Curve for Percent-change from pre-exercise baseline Forced Expiratory Volume in one second (FEV1) in L, from 0 to 20 minutes (AUC0-20)



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Post-exercise Percent Fall in FEV1   [ Time Frame: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10) ]
  Show Outcome Measure 1

2.  Secondary:   Area Under the Curve for Percent-change From Pre-exercise Baseline FEV1 in Liters (L), From 0 to 20 Minutes (AUC(0-20))   [ Time Frame: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10) ]
  Show Outcome Measure 2

3.  Secondary:   Maximum FEV1 Percent Predicted Following First Beta-agonist Use   [ Time Frame: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10) ]
  Show Outcome Measure 3

4.  Secondary:   Time to Recovery to Within 5 Percent of Baseline FEV1   [ Time Frame: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10) ]
  Show Outcome Measure 4

5.  Secondary:   Average (Avg) Percent (%) Change in FEV1 After First Beta (β)-Agonist Use and Prior to Second Beta-agonist Use   [ Time Frame: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10) ]
  Show Outcome Measure 5


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Executive Vice President, Clinical and Quantitative Sciences
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372


No publications provided by Merck

Publications automatically indexed to this study:


Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00127166     History of Changes
Other Study ID Numbers: 2004_006, MK0476-911
Study First Received: June 30, 2005
Results First Received: June 16, 2009
Last Updated: April 7, 2010
Health Authority: Italy: Ministry of Health